Advertisement

Topics

Global CEO Initiative on Alzheimer’s Disease and Optum Labs Company Profile

21:00 EDT 20th June 2018 | BioPortfolio


News Articles [2832 Associated News Articles listed on BioPortfolio]

Global CEO Initiative: Andrea Pfeifer & George Vradenburg. Working together on the global fight to stop Alzheimer’s disease

In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Andrea Pfeifer & George Vradenburg from the Global CEO Initiative

Global Alzheimer’s Disease Epidemiology, Patient Flow, Prevalence and Diagnosed & Treated Patients Analysis – 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Alzheimer’s Disease Epidemiology and Patient Flow Analysis – 2018” report has been added to ResearchAndMarkets.com’s offeri...

New Research Framework Defines Alzheimer's by Brain Changes, Not Symptoms

NewsOnce validated in diverse global populations, this new definition will create a powerful tool to speed and improve the development of disease-modifying treatments for Alzheimer's disease.

New definition of Alzheimer's changes how disease is researched

When you think of dementia, most people automatically think of Alzheimer's disease, too. But, under a new definition of Alzheimer's, the two terms no longer will be considered interchangeable. The new...

Ex-GSK CEO Witty named head of pharmacy benefit firm Optum

Current Optum CEO Larry Renfro will move to Optum Ventures as MD

Survey finds reducing stigma attributed to Alzheimer's is vital to prevention research

(Alzheimer's Association) Stigma associated with Alzheimer's disease may be an obstacle for individuals to seek information about their risk of developing Alzheimer's disease and to participate in cli...

Sex matters: Addressing the Alzheimer's disease research gap

(Society for Women's Health Research) To prevent and treat Alzheimer's disease, scientists need to better understand how the disease differs between women and men, according to a paper published June ...

Building A Community-Focused Clinical Trial Network For Alzheimer's Disease

Clinical Informatics News | Dementia-related disorder trials, especially Alzheimer’s, are harder to recruit for and complete due to dementia’s unique characteristics and psychological effects...

Drugs and Medications [430 Associated Drugs and Medications listed on BioPortfolio]

Sure antiperspirant deodorant unscented [Idelle Labs, Ltd]

Sure Aerosol Antiperspirant Deodorant Unscented

Sure antiperspirant deodorant regular [Idelle Labs, Ltd]

Sure Aerosol Antiperspirant Deodorant Regular Scent

Ammens medicated powder shower fresh formula [Idelle Labs, Ltd]

Ammens Medicated Powder Shower Fresh Formula

Ammens medicated powder original [Idelle Labs, Ltd]

Ammens Medicated Powder

Brut anti-perspirant and deodorant [Idelle Labs, Ltd]

Brut Anti-perspirant and Deodorant

PubMed Articles [4950 Associated PubMed Articles listed on BioPortfolio]

Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.

We conducted Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) and compared the basic characteristics and progression profiles with those of ADNI in North America.

Mapping longitudinal scientific progress, collaboration and impact of the Alzheimer's disease neuroimaging initiative.

Alzheimer's disease neuroimaging initiative (ADNI) is a landmark imaging and omics study in AD. ADNI research literature has increased substantially over the past decade, which poses challenges for ef...

Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.

Neuroimaging modalities can measure different aspects of the disease process in Alzheimer's disease, although the relationship between these modalities is unclear.

Associations of Pulse and Blood Pressure with Hippocampal Volume by APOE and Cognitive Phenotype: The Alzheimer's Disease Neuroimaging Initiative (ADNI).

It is increasingly evident that high blood pressure can promote reduction in global and regional brain volumes. While these effects may preferentially affect the hippocampus, reports are inconsistent.

Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.

Chronic neuroinflammation has been implicated in Alzheimer's disease (AD) pathology.

Clinical Trials [4467 Associated Clinical Trials listed on BioPortfolio]

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used...

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continu...

Effects of ONO-2506PO in Patients With Alzheimer's Disease

The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

The purpose of this study is to assess the efficacy of galantamine on the attention of patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease patients a...

Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's

Determine effect and duration of effect of timed therapeutic light compared to control light on parameters of circadian rhythmicity, physiologic plasticity, sleep, and global function in w...

Companies [2673 Associated Companies listed on BioPortfolio]

Global CEO Initiative on Alzheimer’s Disease and Optum Labs

Optum Labs

Optum Labs was established through a partnership between Optum, a leading information and technology-enabled health services business, and Mayo Clinic, a nonprofit worldwide leade...

Optum Jeffrey Smith Optum (773) 907-0860jeffrey.p.smith@optum.com

Optum (www.optum.com) is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. Optum c...

Optum and QSSI, Inc.

Optum is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. With more than 50,000 people w...

Optum / Mayo Clinic

Optum (www.optum.com) is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. Optum c...

More Information about "Global CEO Initiative on Alzheimer’s Disease and Optum Labs" on BioPortfolio

We have published hundreds of Global CEO Initiative on Alzheimer’s Disease and Optum Labs news stories on BioPortfolio along with dozens of Global CEO Initiative on Alzheimer’s Disease and Optum Labs Clinical Trials and PubMed Articles about Global CEO Initiative on Alzheimer’s Disease and Optum Labs for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Global CEO Initiative on Alzheimer’s Disease and Optum Labs Companies in our database. You can also find out about relevant Global CEO Initiative on Alzheimer’s Disease and Optum Labs Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record